Estimating the global and regional impact of introducing typhoid conjugate vaccination schedules: a modelling study
Year: 2026
Type: article
Abstract: BACKGROUND: In 2018, WHO recommended single-dose typhoid conjugate vaccines (TCVs) for typhoid-endemic countries. Emerging evidence of waning immunity has raised questions about optimal vaccination age and booster doses. A follow-up multi-model study evaluated vaccination schedules, focusing on booster strategies. Here, we expand findings from one of four modelling groups, estimating the global and regional health impact of TCV schedules. METHODOLOGY: We developed an agent-based typhoid transmission model using the open-source Starsim toolbox. The model captures subclinical and acute infections, chronic carriers, and natural and vaccine-derived immunity, with age- and sex-specific parameters and outcomes. The model was calibrated to three incidence archetypes (medium, high, and very high) and two vaccine-derived immunity durations (fast and slow waning). Countries were mapped to archetypes based on national typhoid burden. We compared no vaccination with four strategies: routine vaccination at 9 months, 9 months with a booster at 5 years, 2 years, and 5 years, each with a catch-up campaign. Cases, deaths, and DALYs averted were estimated globally and across GBD super-regions over 10 years. RESULTS: Globally, up to 29.5 million cases and 8.2 million DALYs could be averted with routine vaccination at 9 months plus a 5-year booster. Earlier vaccination and longer-lasting immunity generally increased impact. Under fast waning, vaccination at 2 years averted more cases and DALYs than vaccination at 9 months or 5 years, particularly in high-incidence settings where burden was greatest among children aged 2-<5 years. Boosters provided additional benefits, especially with fast waning. South Asia accounted for the largest share of global impact, followed by Sub-Saharan Africa. CONCLUSION: TCV could avert substantial typhoid burden. The optimal age for a single dose depends on how quickly protection wanes, and boosters add benefit where waning is rapid. Better evidence on the protection duration, and country-specific analyses, are needed to guide schedule choices.
Source: Vaccine
Authors: Alina M. Muellenmeister(Formal analysis, Investigation, Methodology, Software, Visualization, Writing – original draft, Writing – review & editing), Nick Scott(Conceptualization, Methodology, Supervision, Writing – review & editing), Romesh G. Abeysuriya(Conceptualization, Methodology, Supervision, Writing – review & editing)
Institutions: Burnet Institute, Monash University
Language: English
Subfield: Food Science
Domain: Life Sciences
Open Access status: hybrid
Estimated APC paid: $3,620
OpenAlex ID: W7204899920
